(Hypertension. 1997;29:268.)
© 1997 American Heart Association, Inc.
Arthur C. Corcoran Memorial Lecture |
Endogenous Estrogen and Acetylcholine-Induced Vasodilation in Normotensive Women
From I Clinica Medica (S.P., A.V., L.G., G.B., S.T., A.S.) and the Department of Obstetrics and Gynaecology (M.L., A.R.G.), University of Pisa; and the Department of Obstetrics and Gynaecology, University of Modena (F.P.), Italy.
Correspondence to Stefania Pinto, MD, I Clinica Medica, University of Pisa, Via Roma, 67, 56100 Pisa, Italy
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Acute exogenous estrogen administration enhances endothelial function in postmenopausal women. To evaluate the effect of endogenous estrogen on endothelium-dependent vasodilation, in 10 fertile normotensive women (age range 45 to 51 years) we studied the changes in forearm blood flow (strain-gauge plethysmography) induced by intrabrachial acetylcholine (0.15, 0.45, 1.5, 4.5, 15 µg·100 mL-1·min-1), an endothelium-dependent vasodilator, or sodium nitroprusside (1, 2, 4 µg·100 mL-1·min-1), an endothelium-independent vasodilator, in basal conditions and within 1 month after ovariectomy. As control subjects, 10 matched healthy women were also evaluated. In basal condition, vasodilation to acetylcholine and sodium nitroprusside was similar in patients and control subjects. Ovariectomy was followed by endogenous estrogen deprivation (from 71.6±31.3 to <12 pg/mL) and was associated with a significant (P<.01) reduction in acetylcholine-induced vasodilation compared with baseline (maximum percent increase in forearm blood flow: baseline 568.2±47.1%; ovariectomy 309.5±37.4%); the response to sodium nitroprusside was unaffected by ovariectomy (maximum percent increase in forearm blood flow: baseline 526.4±36.5%; ovariectomy 454.7± 47.2%; P=NS). In 6 of 10 patients, the study was repeated after 3 months of estrogen replacement therapy (17ß-estradiol, 50 µg/d by transdermal patches). Exogenous estrogen restored acetylcholine-induced vasodilation (maximum percent increase in forearm blood flow: 548.9±43.1%; P<.01 versus ovariectomy), which was no longer different from baseline, whereas the response to sodium nitroprusside was not affected (maximum percent increase in forearm blood flow: 480.2±39.3%; P=NS). These results suggest a protective role of endogenous estrogen on endothelium-dependent vasodilation in the forearm vascular bed of normotensive women.
Key Words: endothelium • acetylcholine • estrogen • sodium nitroprusside
Abbreviations: CVD = cardiovascular disease • ERT = estrogen replacement therapy • FBF = forearm blood flow • LDL = low-density lipoprotein • NO = nitric oxide • NS = not significant
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Epidemiological investigations have demonstrated that menopause is associated with an increased risk of CVD, showing that sex differences in the incidence and severity of CVD are no longer found after menopause.1,2 Moreover, women who undergo early menopause, either surgically or naturally, are at increased risk of developing coronary heart disease in comparison with premenopausal women of the same age.3 Sex-hormone deficiency, independently of aging, seems therefore to be responsible for the enhanced risk of CVD, as also suggested by the favorable effects of ERT on cardiovascular morbidity and mortality.4,5
Although there is increasing evidence of the protection afforded by ERT against CVD, the underlying mechanisms remain not fully explained. Estrogens are believed to play a protective role on the cardiovascular system mainly by a beneficial action on lipid profile, especially by favorably affecting plasma concentration of lipoproteins, by interfering with cholesterol deposition in the arterial wall and by preserving LDL from oxidation.6–8 Besides these lipid-mediated effects, recent data point to a direct vascular action of estrogens, which have been demonstrated to improve vascular reactivity, possibly by calcium channel blocking-like action9 and/or by interplaying with endothelial vasoactive factors.10,11
It is now well documented that the endothelium plays a primary role in the modulation of vascular tone through the production of different factors, of which the most important is NO, a labile substance released by endothelial cells during the catabolism of L-arginine into citrulline through the activity of the NO synthase enzyme.12 There is clinical and experimental evidence suggesting that exogenous estrogens affect endothelium-dependent vasodilation of peripheral and coronary arteries in estrogen-deficient animals13–15 and in menopausal women.16–19 Acute estrogen administration has been reported to improve vasoreactivity in healthy postmenopausal women at dosages achieving serum concentrations typical of the midcycle of reproductive-age women.20 Moreover, a beneficial effect of acute estrogen administration on myocardial ischemia has been found in postmenopausal women with angiographically proven coronary artery disease.21 On the other hand, endogenous estrogen seems to play a protective role on endothelial function since in normotensive women the age-related impairment of endothelium-dependent vasodilation occurs later in comparison with men, appearing only around the time of menopause.22,23 Moreover, a protective effect of endogenous estrogen has also been shown in essential hypertensive women.22
Therefore, postmenopause is characterized by the loss of an estrogen-dependent mechanism protecting vascular function. However, no reports are yet available on the effect of acute endogenous estrogen deprivation on vasomotor response in women of reproductive age. Thus, this study was planned to assess the effect of surgical menopause on endothelium-dependent vasodilation in fertile women who underwent bilateral ovariectomy for uterine leiomyoma.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
A group of 10 women, aged 47.4±1.6 (range 45 to 51) years, with symptomatic uterine leiomyoma associated with menorrhagia (n=8), pelvic pain (n=1), or rapid increase in size (n=1) was enrolled in the study. All patients had regular menstrual cycles, no history of hypertension, CVD, dyslipidemia, diabetes mellitus, obesity, or any other major systemic illness. As control subjects, we enrolled 10 healthy women, aged 48.2±2.9 (range 43 to 50) years, who were matched for hemodynamic and humoral characteristics (Table 1). No patients had received hormone treatment or had had a pregnancy for at least 6 months before the study. All subjects had been free from any drugs for at least 4 weeks. Only 2 were mild smokers (less than 5 cigarettes a day).
|
In accordance with institutional guidelines, all patients were aware of the investigational nature of the study and gave written consent to it.
Experimental Procedure
All studies were performed at 8:00 AM, after overnight fasting, with the subjects lying supine in a quiet air-conditioned room (22°C to 24°C). A polyethylene cannula (21 gauge, Abbot) was inserted into the brachial artery under local anesthesia (2% lidocaine). The cannula was connected through stopcocks to a pressure transducer (model MS20, Electromedics) for the determination of systemic mean arterial blood pressure (one third pulse pressure plus diastolic pressure) and heart rate (model VSM1, Physiocontrol), and for intra-arterial infusions by a Harvard infusion pump (series 944A, Ealing). FBF was measured in both forearms (experimental and contralateral) by strain-gauge venous plethysmography (LOOSCO, GL LOOS).24 The circulation to the hand was excluded 1 minute before each measurement of FBF by inflating a pediatric cuff around the wrist, at supra-systolic blood pressure. Earlier work has determined the sensitivity and the reproducibility of the method.25
Forearm volume was measured by the water-displacement method, and infusion rates of drugs were normalized to 100 mL of tissue by altering the drug concentration in the solvent, while the speed of infusion was not modified. The drugs used were infused through separate ports via three-way stopcocks at concentrations that had no systemic effects.
Experimental Design
Endothelium-dependent vasodilations were estimated by performing a dose-response curve to intra-arterial acetylcholine (cumulative increase of the infusion rates: 0.15, 0.45, 1.5, 4.5, 15 µg/100 mL forearm tissue per minute, for 5 minutes at each dose),26,27 while endothelium-independent vasodilations were assessed with a dose-response curve to intra-arterial sodium nitro-prusside28 (cumulative increase by 1,2, and 4 µg/100 mL forearm tissue per minute, for 5 minutes each). These rates were selected to induce vasodilation comparable to that obtained with acetylcholine. The sequence of infusion of the two drugs was randomized and 45 minutes of recovery were allowed between the two experimental steps.
Forearm study was performed during the follicular phase in both control subjects and patients. Patients repeated the study within 1 month after ovariectomy (24±2 days). Finally, 6 of 10 patients were studied again 3 months after ERT (transdermal estradiol; TTS 50, 50 µg/24 h).
Data Analysis
Data were analyzed in terms of changes in FBF. Since mean arterial blood pressure did not significantly change during the study, increments in FBF were taken as evidence of local vasodilation. Results were expressed as mean±SD in text and as mean±SEM in the figures and tables. Data were analyzed statistically by the t test for paired or unpaired observations and by ANOVA for repeated measures. Scheffé’s test was applied for multiple comparison testing. A value of P<.05 was considered to be statistically significant.
Drugs
Acetylcholine HCl (Farmigea SpA) and sodium nitroprusside (Malesci) were obtained from commercially available sources and diluted freshly to the desired concentration by adding normal saline. Sodium nitroprusside was dissolved in glucosate solution and protected from light by an aluminum foil.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The systemic demographic, hemodynamic, and humoral characteristics for control subjects and patients are summarized in Table 1. There was no significant difference in baseline values between control subjects and patients. Moreover, after ovariectomy and ERT, there was no statistically significant modification in basal parameters compared with values found before surgery. It is worth noting that no statistical difference in blood pressure values or lipid and glucose profile was observed when basal conditions, ovariectomy, and ERT were compared. Moreover, plasma estradiol values did not differ between control subjects and patients (76.5±34.3 and 71.6±31.3 pg/mL, respectively) and as expected fell to undetectable levels after ovariectomy. Finally, during ERT, plasma estrogen levels were 48.6±13.9 pg/mL.
Response to Intrabrachial Acetylcholine and Sodium Nitroprusside
Vasodilation to acetylcholine was not significantly different between control subjects (FBF rose from 3.6±0.4 to a maximum of 25.1±4.9 mL/100 mL forearm tissue per minute with the highest dose) and patients before surgery (FBF rose from 3.5±0.5 to a maximum of 23.4±4.5 mL/ 100 mL forearm tissue per minute with the highest dose) (Fig 1). The vasodilating effect of the endothelium independent vasodilator sodium nitroprusside was also similar in control subjects and patients (FBF rose from 3.4±0.4 to a maximum of 22.3±3.6 mL/100 mL forearm tissue per minute with the highest dose and from 3.4±0.4 to a maximum of 21.3±3.1 mL/100 mL forearm tissue per minute, respectively; NS) (Fig 1).
|
) (n=10) and female patients with uterine leiomyoma before ovariectomy (•) (n=10). Data are shown as mean±SEM and expressed as absolute values. Asterisks denote a significant difference between healthy control subjects and patients (P<.05).After ovariectomy the response to acetylcholine was significantly (P<.001) blunted compared with preintervention results (maximum to acetylcholine: from 3.4± 0.4 to 13.9±2.8 mL/100 mL forearm tissue per minute) (Fig 2) while the vasodilation to sodium nitroprusside was not altered (maximum to sodium nitroprusside: from 3.5±0.4 to 19.4±3.7 mL/100 mL forearm tissue per minute) (Fig 2).
|
Finally, the effect of ERT was evaluated in a subgroup of our study population (6 of 10) (Table 2). In these subjects, vasodilation to acetylcholine, which before ovariectomy was similar to values observed in control subjects (maximum to acetylcholine: from 3.6±0.4 to 25.8±3.9 mL/100 mL forearm tissue per minute), was found to be significantly blunted after surgery (maximum to acetylcholine: from 3.3±0.4 to 14.7±2.4 mL/100 mL forearm tissue per minute; P<.05 versus preovariectomy) (Fig 3). However, after 3 months of ERT the vasodilating effect of acetylcholine was significantly (P<.02) increased compared with postovariectomy results (maximum to acetylcholine: from 3.5±0.5 to 25.5±3.1 mL/100 mL forearm tissue per minute) (Fig 3) and it is worth noting that it was no longer statistically different compared with preovariectomy values (Fig 3). In contrast, in the same subgroup of patients, the response to sodium nitroprusside (maximum to sodium nitroprusside: from 3.4±0.4 to 22.4±3.1 mL/100 mL forearm tissue per minute) observed before ovariectomy was unchanged either after surgery (maximum to sodium nitroprusside: from 3.1± 0.4 to 19.2±2.8 mL/100 mL forearm tissue per minute; NS versus preovariectomy) or ERT (maximum to sodium nitroprusside: from 3.4±0.4 to 23.6±3.2 mL/100 mL forearm tissue per minute; NS versus preovariectomy or postovariectomy) (Fig 3).
|
|
). Data are shown as mean±SEM and expressed as absolute values. Asterisks denote a significant difference between patients before and after ovariectomy or after ERT (P<.05). |
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study was designed to test the effect of acute endogenous estrogen deprivation on endothelium-dependent vasodilation in women in reproductive age. Therefore, in a group of female patients who underwent bilateral ovariectomy for uterine leiomyoma, we evaluated the forearm vascular response to acetylcholine and sodium nitroprusside, an endothelium-dependent and -independent vasodilator, respectively. As control subjects we selected healthy women well matched with the study group population for demographic and clinical parameters. Particular attention was paid to risk factors impairing endothelial function such as age, blood pressure, phase of the menstrual cycle, lipid and glucose profile, and smoking history. In the two study populations, the response to acetylcholine and sodium nitroprusside was similar, indicating preserved endothelium-dependent vasodilation in patients with leiomyoma. In contrast, after bilateral ovariectomy, the response to acetylcholine was found to be reduced compared with preintervention results. Since the vasodilating effect of sodium nitroprusside remained unchanged, this finding suggests that acute estrogen deprivation leads to selective impairment of endothelium-dependent vasodilation. This possibility is further confirmed by results obtained after ERT. Thus, in a subgroup of ovariectomized patients (6 of 10), ERT significantly increased the response to acetylcholine compared with that observed after ovariectomy. Moreover, the effect of acetylcholine after ERT was no longer different compared with the response observed in basal conditions (before ovariectomy) or in the control group. Since again the vasodilating effect of sodium nitroprusside did not change, these findings not only indicate that ERT restores endothelium-dependent vasodilation in short term estrogen deprived women but also further confirm the positive effect of estrogen on endothelial function.
The most likely explanation for the beneficial effect of estrogen on endothelium-dependent vasodilation, as observed in our experimental conditions, is represented by a direct effect of the hormone on endothelial function. Although the exact mechanism by which endogenous estrogen protects the endothelium cannot be determined from the present study, experimental evidence indicates that administration of estrogen upregulates the transcription of NO synthase, the key enzyme regulating NO production.29 In addition, a further possible explanation is suggested by the finding that estrogen has antioxidant properties and may preserve endothelium-dependent vasodilation through the negative effect of superoxide anions that strongly inactivate NO.30
An alternative explanation may be represented by an indirect estrogen effect mediated by lipid profile changes associated with sex hormone deprivation or replacement. Estrogen may directly improve lipid profile by decreasing plasma concentrations of total and LDL cholesterol while increasing high-density lipoprotein cholesterol, and inhibiting oxidation of the LDL fraction.6,8 Since both plasma lipid concentration and oxidative LDL status may directly impair endothelial function, the possibility exists that an estrogen-mediated beneficial effect on these parameters could improve endothelium-dependent vasodilation. While the possibility of an estrogen effect on lipid plasma concentration is very unlikely in our experimental conditions, since the short periods of estrogen deprivation and replacement (1 and 3 months, respectively) do not induce significant and clinically relevant changes in the lipid profile (see Table 1), a possible reduction of LDL oxidation cannot be ruled out by the present study. A final indirect possibility may be an estrogen-mediated effect on blood pressure values or glucose profile. How-ever, the present findings indicating that these parameters did not significantly change throughout the study seem to be sufficient to exclude this possibility.
The possibility of a direct effect of sex hormones on endothelial function, as suggested by the impairment in vasodilating response after acute estrogen deprivation, is in keeping with the finding of increased endothelium-dependent vasodilation after acute infusion of estradiol in cynomolgus monkeys15 and in postmenopausal women.18,20,21 Moreover, physiological changes in endogenous estrogen during the menstrual cycle have recently been found to correlate positively with flow-mediated vasodilation in the absence of lipid modifications, accounting for a direct action of estradiol in modulating endothelial function.31
Only few reports are available so far on the effect of chronic estrogen administration on the endothelium of ovariectomized experimental animals and postmenopausal women undergoing replacement therapy. An improvement in endothelium-dependent vasodilation after chronic estrogen administration has been found in atherosclerotic coronary arteries of ovariectomized monkeys14 and in both the brachial artery16 and epicardial coronary arteries17–19 of postmenopausal women.16,19 In contrast, a recent report from Gilligan et al32 failed to demonstrate an increased vasodilating response to acetylcholine in postmenopausal women after 3 weeks of ERT by transdermal estradiol administered at an even higher dose as in our present investigation. Although this study seems to be at variance with our results, both the different population characteristics, mainly age and time elapsed since menopause and the different length of ERT could account for the different findings. Thus, increasing age is associated with a decline in endothelium-dependent vasodilation,33,34 and this alteration is amplified in postmenopausal women.22 Therefore, it is important to observe that we studied younger women shortly after ovariectomy-induced menopause, while Gilligan et al evaluated an older study population, in most of whom menopause occurred years before. Furthermore some evidence suggests that estrogen receptor levels within the vasculature may be closely related to the hormonal milieu and may require a period of estrogen priming.35,36 Therefore, both the number of months or years since menopause and a more lasting exogenous estrogen exposure may be crucial in regulating receptor exposure to exogenous estrogen administration. The difference in age and duration of menopause of the present study population compared with that evaluated by Gilligan et al32 and the different period of treatment can thus be taken into account to explain the discrepancy in the results.
Endothelial dysfunction has been demonstrated in pathological conditions to be associated with an increased risk of CVD.33,34,37–40 The pivotal role of endothelium in the pathogenesis of vascular disease has been well documented by elucidating its contribution to control of the interaction between blood and the vessel wall.41 The impaired endothelial responses associated with the ovarian estrogen loss may contribute to explaining the rise in incidence and severity of CVD in women who have early surgical menopause. Thus, there is evidence suggesting that the demonstrated endothelial dysfunction at forearm level may reflect a more diffuse vascular alteration, as indicated by a report showing a close relationship between brachial artery flow-mediated vasodilation and endothelial changes in coronary arteries.42
Our study, performed roughly 1 month after ovariectomy, allows the hypothesis of a direct effect of sex hormone deprivation on vascular reactivity, occurring before lipid pattern changes, and provides further evidence of an estrogen action on endothelial function by the findings of a positive effect of 3-month ERT.
In conclusion, these findings indicate that endothelium-dependent vasodilation in women is inlhrenced by hormonal status, which positively modulates endothelial function, suggesting that these mechanisms may be at least partially responsible for the protective role of estrogen in the development of CVD in women.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Kannel WB, Hjortland MC, McNamara PM. Menopause and the risk of cardiovascular disease: the Framingham Study. Ann Intern Med. 1976; 8S : 447 –456.
2. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986; 111 : 383 –390.[Medline] [Order article via Infotrieve]
3. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987; 316 : 1105 –1110.[Abstract]
4. Stampfer MJ, Golditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health Study. N Engl J Med. 1991; 325 : 756 –762.[Abstract]
5. Grodstein F, Stampfer MJ. The epidemiology of coronary artery disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995; 38 : 199 –210.[Medline] [Order article via Infotrieve]
6. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive estrogen use in women: results from the Lipid Research Clinics Program Follow-up Study.
Circulation. 1987;
75
: 1102
–1109.
7. Adams MR, Kaplan JR, Manuck SB, Koritnik DB, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17ß-estradiol in ovariectomized monkeys: lack of an effect of added progesterone.
Arteriosclerosis. 1990;
10
: 1051
–1057.
8. Sack MN, Rader DJ, O Cannon R III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994; 343 : 269 –270.[Medline] [Order article via Infotrieve]
9. Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen: a calcium antagonist effect? Lancet. 1993; 341 : 1264 –1265.[Medline] [Order article via Infotrieve]
10. Ylikorkala O, Puolakka J, Vrinikka L. Vasoconstrictory thromboxane A2 and vasodilatory prostacyclin in climacteric women: effect of oestrogen-progestogen therapy. Maturitas. 1984; 5 : 201 –205.[Medline] [Order article via Infotrieve]
11. Poldermann KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothehn levels.
Ann Intern Med. 1993;
118
: 429
–432.
12. Lüscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, Fla: CRC Press; 1990: 1 –228.
13. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17ß-estradiol on endothelium-dependent responses in the rabbit.
J Pharmacol Exp Ther. 1988;
244
: 19
–22.
14. Williams JK, Adams MR, Klopfenstein HB. Estrogen modulates responses of atherosclerotic coronary arteries. Circularion. 1990; 81 : 1680 –1687.
15. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women.
Ann Intern Med. 1994;
121
: 936
–941.
16. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women.
Circulation. 1994;
89
: 52
–60.
17. Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17ß-Estradiol attenuates acetyl-choline-induced coronary arterial constriction in women but not men with coronary heart disease. Circularion. 1995; 92 : 24 –30.
18. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol. 1994; 73 : 951 –952.[Medline] [Order article via Infotrieve]
19. Williams JK, Adams MR. Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992; 20 : 452 –457.[Abstract]
20. Gilligan DM, Qyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women.
Circulation. 1994;
89
: 2545
–2551.
21. Gilligan DM, Badar DM, Panza JA, Qyyumi AA, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women.
Circulation. 1994;
90
: 786
–791.
22. Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, Pinto S, Salvetti A. Menopause is associated with endothelial dysfunction in women.
Hypertension. 1996;
28
: 576
–582.
23. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994; 24 : 471 –476.[Abstract]
24. Whitney RJ. The measurement of volume changes in human limbs.
J Physiol (Lond). 1953;
121
: 1
–27.
25. Pedrinelli R, Taddei S, Graziadei L, Salvetti A. Vascular responses to ouabain and norepinephrine in low and normal renin hypertension.
Hypertension. 1986;
8
: 786
–792.
26. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle bv acetvlcholine. Nature. 1980; 288 : 373 –376.[Medline] [Order article via Infotrieve]
27. Valiance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989; 2 : 997 –1000.[Medline] [Order article via Infotrieve]
28. Schultz KD, Schultz K, Schultz G. Sodium nitroprusside and other smooth muscle relaxants increase cyclic GMP levels in rat ductus deferens. Nature. 1977; 265 : 750 –751.[Medline] [Order article via Infotrieve]
29. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988; 333 : 664 –666.[Medline] [Order article via Infotrieve]
30. Ghin JH, Azhar S, Hoffman BB. Inactivation of endothelium derived relaxing factor by oxidized lipoproteins. J Clin Invest. 1992; 89 : 10 –18.[Medline] [Order article via Infotrieve]
31. Hashimoto M, Akishita M, Eto M, Ishikawa M. Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H, Ouchi Y. Modulation of endothelium-dependent flow-mediated dilation of the brachial artery by sex and menstrual cycle.
Circulation. 1995;
92
: 3431
–3435.
32. Gilligan DM, Badar DM, Panza JA, Qyyumi AA, Cannon RO III. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol. 1995; 75 : 264 –268.[Medline] [Order article via Infotrieve]
33. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Basile Fasolo C, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension.
Circulation. 1995;
91
: 1981
–1987.
34. Gerhard M, Roddy M-A, Creager S, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans.
Hypertension. 1996;
27
: 849
–853.
35. White MM, Zamudio S, Stevens T, Tyler R, Lindenfeld J, Leslie K, Moore LG. Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms.
Endocr Rev. 1995;
16
: 739
–764.
36. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones.
Proc Nat Acad Sci USA. 1994;
91
: 5212
–5216.
37. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension.
Hypertension. 1993;
21
: 929
–933.
38. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM. Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990; 86 : 228 –234.[Medline] [Order article via Infotrieve]
39. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Circulation. 1993;
88
: 2510
–2516.
40. Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function.
Circulation. 1995;
92
: 1094
–1100.
41. Cohen R. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis. 1995; 38 : 105 –128.[Medline] [Order article via Infotrieve]
42. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delgrange D, Lieberman E, Ganz P, Creager MA, Yeung AC, Selwyn AP. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995: 26 : 1235 –1241.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  V. Ricchiuti, C. G Lian, E. M Oestreicher, L. Tran, J. R Stone, T. Yao, E. W Seely, G. H Williams, and G. K Adler Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats J. Endocrinol., January 1, 2009; 200(1): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shibasaki, D. A. Low, S. L. Davis, and C. G. Crandall Nitric oxide inhibits cutaneous vasoconstriction to exogenous norepinephrine J Appl Physiol, November 1, 2008; 105(5): 1504 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Torgrimson, J. R. Meendering, P. F. Kaplan, and C. T. Minson Endothelial function across an oral contraceptive cycle in women using levonorgestrel and ethinyl estradiol Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2874 - H2880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J Pearson, C. Rait, M G. Nicholls, T. G Yandle, and J. J Evans Regulation of adrenomedullin release from human endothelial cells by sex steroids and angiotensin-II. J. Endocrinol., October 1, 2006; 191(1): 171 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gimenez, M. P. Garcia, M. Serna, B. Bonacasa, L. F. Carbonell, T. Quesada, and I. Hernandez 17{beta}-Oestradiol enhances the acute hypotensive effect of captopril in female ovariectomized spontaneously hypertensive rats Exp Physiol, July 1, 2006; 91(4): 715 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V L Clifton, R Crompton, M A Read, P G Gibson, R Smith, and I M R Wright Microvascular effects of corticotropin-releasing hormone in human skin vary in relation to estrogen concentration during the menstrual cycle J. Endocrinol., July 1, 2005; 186(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rickenlund, M. J. Eriksson, K. Schenck-Gustafsson, and A. L. Hirschberg Oral Contraceptives Improve Endothelial Function in Amenorrheic Athletes J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3162 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rogers and D. D. Sheriff Role of estrogen in nitric oxide- and prostaglandin-dependent modulation of vascular conductance during treadmill locomotion in rats J Appl Physiol, August 1, 2004; 97(2): 756 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Kalantaridou, K. K. Naka, E. Papanikolaou, N. Kazakos, M. Kravariti, K. A. Calis, E. A. Paraskevaidis, D. A. Sideris, A. Tsatsoulis, G. P. Chrousos, et al. Impaired Endothelial Function in Young Women with Premature Ovarian Failure: Normalization with Hormone Therapy J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3907 - 3913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Kirwan, N. J. MacLusky, H. M. Shapiro, B. L. Abramson, S. G. Thomas, and J. M. Goodman Acute and Chronic Effects of Hormone Replacement Therapy on the Cardiovascular System in Healthy Postmenopausal Women J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1618 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Chambliss and P. W. Shaul Estrogen Modulation of Endothelial Nitric Oxide Synthase Endocr. Rev., October 1, 2002; 23(5): 665 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.C. Duncan, J.R. Petrie, M.J. Brosnan, A.M. Devlin, R.A. Bass, D.S. Charnock-Jones, J.M.C. Connell, A.F. Dominiczak, and M.A. Lumsden Is estradiol cardioprotection a nitric oxide-mediated effect? Hum. Reprod., July 1, 2002; 17(7): 1918 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington, M. A. Espeland, J. R. Crouse III, J. Robertson, W. A. Riley, M. A. McBurnie, and G. L. Burke Estrogen Replacement and Brachial Artery Flow-Mediated Vasodilation in Older Women Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1955 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Beyer, G. Yu, H. Hanke, and H. M. Hoffmeister Acute Gender-Specific Hemodynamic and Inotropic Effects of 17{beta}-Estradiol on Rats Hypertension, November 1, 2001; 38(5): 1003 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Chan, R. J. MacAllister, H. M. Colhoun, P. Vallance, and A. D. Hingorani Changes in Endothelium-Dependent Vasodilatation and {{alpha}}-Adrenergic Responses in Resistance Vessels during the Menstrual Cycle in Healthy Women J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2499 - 2504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Weitz, M. Elam, J. Born, H. L. Fehm, and C. Dodt Postmenopausal Estrogen Administration Suppresses Muscle Sympathetic Nerve Activity J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 344 - 348. [Abstract] [Full Text]
|
|
|
|
|
|
K. J. Mather, E. G. Norman, J. C. Prior, and T. G. Elliott Preserved Forearm Endothelial Responses with Acute Exposure to Progesterone: A Randomized Cross-Over Trial of 17-{beta} Estradiol, Progesterone, and 17-{beta} Estradiol with Progesterone in Healthy Menopausal Women J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4644 - 4649. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. O. Steinberg, G. Paradisi, J. Cronin, K. Crowde, A. Hempfling, G. Hook, and A. D. Baron Type II Diabetes Abrogates Sex Differences in Endothelial Function in Premenopausal Women Circulation, May 2, 2000; 101(17): 2040 - 2046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Charkoudian, D. P. Stephens, K. C. Pirkle, W. A. Kosiba, and J. M. Johnson Influence of female reproductive hormones on local thermal control of skin blood flow J Appl Physiol, November 1, 1999; 87(5): 1719 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Case and C. A. Davison Estrogen Alters Relative Contributions of Nitric Oxide and Cyclooxygenase Products to Endothelium-Dependent Vasodilation J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 524 - 530. [Abstract] [Full Text]
|
|
|
|
|
|
S. C. Lim, A. E. Caballero, S. Arora, P. Smakowski, E. M. Bashoff, F. M. Brown, F. W. Logerfo, E. S. Horton, and A. Veves The Effect of Hormonal Replacement Therapy on the Vascular Reactivity and Endothelial Function of Healthy Individuals and Individuals with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4159 - 4164. [Abstract] [Full Text]
|
|
|
|
|
|
N. J. Brown, J. V. Gainer, C. M. Stein, and D. E. Vaughan Bradykinin Stimulates Tissue Plasminogen Activator Release in Human Vasculature Hypertension, June 1, 1999; 33(6): 1431 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Manau, J. Balasch, V. Arroyo, W. Jiménez, F. Fábregues, R. Casamitjana, M. Creus, and J. A. Vanrell Circulatory Dysfunction in Asymptomatic in Vitro Fertilization Patients. Relationship with Hyperestrogenemia and Activity of Endogenous Vasodilators J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1489 - 1493. [Abstract] [Full Text]
|
|
|
|
|
|
N. Charkoudian and J. M. Johnson Modification of active cutaneous vasodilation by oral contraceptive hormones J Appl Physiol, December 1, 1997; 83(6): 2012 - 2018. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||